Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01842308 · ClinicalTrials.gov registry record · Phase 1

Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

A Phase 1 study of Refractory Plasma Cell Myeloma and DS Stage I Plasma Cell Myeloma, sponsored by Mayo Clinic.

Completed
Registry status
Phase 1
Development phase
50
Enrollment target
2
Study locations

NCT01842308 is a Phase 1 study of Refractory Plasma Cell Myeloma and DS Stage I Plasma Cell Myeloma that has completed, run by Mayo Clinic. The registered enrollment target is 50 participants, above the 45-participant average among 25 other Refractory Plasma Cell Myeloma trials with a reported enrollment target (11% higher). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01842308, a Phase 1 study of Refractory Plasma Cell Myeloma and DS Stage I Plasma Cell Myeloma, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 1
Development phase
50 participants
Enrollment target
2
Study locations

Study Summary

This phase I/II trial studies the side effects and best dose of carfilzomib when given together with melphalan and to see how well they work in treating patients with multiple myeloma before stem cell transplant. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving carfilzomib together with melphalan may kill more cancer cells.

Conditions Studied

Refractory Plasma Cell Myeloma DS Stage I Plasma Cell Myeloma DS Stage II Plasma Cell Myeloma DS Stage III Plasma Cell Myeloma

Interventions

  • DRUG Melphalan
  • OTHER Laboratory Biomarker Analysis
  • DRUG Carfilzomib
  • PROCEDURE Autologous Hematopoietic Stem Cell Transplantation
  • PROCEDURE Autologous Bone Marrow Transplantation

Study Locations (2)

Florida

  • Mayo Clinic in Florida - Jacksonville

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2013-06-04
Est. Completion 2019-10-28
Phase Phase 1

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01842308

The ClinicalTrials.gov registry entry for NCT01842308 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 45-participant average among 25 other Refractory Plasma Cell Myeloma trials with a reported enrollment target (11% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Refractory Plasma Cell Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Melphalan is the first listed.

NCT01842308 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Minnesota.

Frequently Asked Questions

What is clinical trial NCT01842308 about?

NCT01842308 is a clinical study titled "Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma". This phase I/II trial studies the side effects and best dose of carfilzomib when given together with melphalan and to see how well they work in treating patients with multiple myeloma before stem cell transplant. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed ...

What is the current status of trial NCT01842308?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2013-06-04. Estimated completion is 2019-10-28.

What conditions does trial NCT01842308 study?

This clinical trial studies the following conditions: Refractory Plasma Cell Myeloma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma.

What interventions are being tested in trial NCT01842308?

The interventions under investigation include: Melphalan (DRUG), Laboratory Biomarker Analysis (OTHER), Carfilzomib (DRUG), Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE), Autologous Bone Marrow Transplantation (PROCEDURE).

Who is sponsoring clinical trial NCT01842308?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01842308 being conducted?

This trial has 2 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Refractory Plasma Cell Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Refractory Plasma Cell Myeloma

All registered trials for this condition

DS Stage I Plasma Cell Myeloma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.